SUNPG 1623

Drug Profile

SUNPG 1623

Alternative Names: SUNPG 1623 I; SUNPG 1623 II; SUNPG 1623 III; SUNPG 1623 IV; SUNPG1623

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Sun Pharmaceutical Industries
  • Class Anti-inflammatories
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Psoriatic arthritis

Most Recent Events

  • 07 Dec 2016 Sun Pharma Global FZE plans a phase IIb trial for Psoriatic arthritis (Adjunctive treatment) in USA (NCT02980692)
  • 30 Nov 2016 Investigation in Psoriatic arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top